Details Basic Details Date Thursday, October 31, 2024 Medical Product Zynquista (sotagliflozin) Health Outcome(s) diabetic ketoacidosis (DKA) Meeting Details View the Advisory Committee Meeting materials here Additional Information Related Link(s) Sentinel Drug Study: Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors & Diabetic Ketoacidosis (DKA) and Use in Type 1 Diabetes Mellitus (T1DM) Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee: SGLT-2 Inhibitors and Diabetic Ketoacidosis (January 17, 2019)